文献速递临床试验与 GCP

III期结肠癌根治术后奥沙利铂辅助方案后替加氟-尿嘧啶维持治疗对比观察:随机对照试验研究方案

Maintenance tegafur-uracil versus observation following an adjuvant oxaliplatin-based regimen in patients with stage III colon cancer after radical resection: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2017-04-26

本研究为在台湾开展的多中心、开放标签、随机、双臂III期试验,评估III期结肠癌根治术后完成3周奥沙利铂辅助方案后,替加氟-尿嘧啶维持治疗1年对比观察的DFS、OS及安全性。计划按2:1随机分配至A组(维持治疗,364例)或B组(观察,182例)。

要点

  • III期结肠癌根治术后完成奥沙利铂辅助方案且无复发者,随机接受替加氟-尿嘧啶维持治疗1年或观察。
  • 主要评估无病生存期、总生存期及安全性。
  • 计划入组A组364例、B组182例,随机比例2:1。

核心结论

  • 作者认为奥沙利铂联合替加氟-尿嘧啶辅助化疗预期安全且疗效高,具有有利缓解率和可耐受毒性特征的优点。

研究设计与样本

  • 多中心、开放标签、随机、对照、双臂III期研究,在台湾开展。
  • 完成3周奥沙利铂辅助方案且无明确疾病复发的合格患者,按2:1随机分配至A组(维持治疗,364例)或B组(观察,182例)。
  • A组治疗在随机化后7天内开始。
  • 研究期间出现疾病复发、不可耐受毒性、撤回知情同意或研究者判定应退出者退出研究,数据不再使用且不得重新入组。

关键数值与推荐

  • A组(维持治疗)替加氟-尿嘧啶维持治疗1年,计划364例。
  • B组(观察组)观察,计划182例。
  • 随机比例2:1。
  • 主要评估无病生存期、总生存期及安全性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We conducted a prospective randomized study of an adjuvant oxaliplatin-based regimen plus orally administered tegafur-uracil in patients with stage III colon cancer after radical resection to evaluate the feasibility of this drug combination in cancer clinical outcomes, acute toxicity, disease-free survival (DFS), and overall survival (OS) in Taiwan. METHODS/DESIGN: This is an open-label, randomized, comparative, double-arm, multicenter, phase III study to assess DFS, OS, and safety profiles of the aforementioned drug combination as maintenance therapy for 1 year in patients with stage III colon cancer after radical resection in Taiwan. Following the completion of an adjuvant oxaliplatin-based regimen for 3 weeks with no evident disease recurrence, all eligible patients will be randomly assigned to either arm A (maintenance therapy) or arm B (observation arm) in a 2:1 ratio (364 and 182 patients in the tegafur-uracil and observation groups, respectively). Treatment in arm A will be started within 7 days of randomization. If the patients reported disease recurrence, intolerable toxicity, withdrew consent or the investigator determined that the patient should be withdrawn during the study period, they were withdrawn from the study. If a patient was discontinued from the study, the corresponding data were not reused, and the patient was not allowed to re-enter the study. DISCUSSION: A unique characteristic of this intervention was that the adjuvant chemotherapy with oxaliplatin and tegafur-uracil was anticipated to be safe and has high treatment efficacy, with the advantage of yielding a favorable response rate and tolerable toxicity profile. TRIAL REGISTRATION: ClinicalTrials.gov, identifier: NCT02836977 . Registered on 18 July 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Yeh YS, Tsai HL, Huang CW, et al. Maintenance tegafur-uracil versus observation following an adjuvant oxaliplatin-based regimen in patients with stage III colon cancer after radical resection: study protocol for a randomized controlled trial. Trials. 2017. PMID: 28441966. doi:10.1186/s13063-017-1904-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。